Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Core Viewpoint - The company forecasts a revenue of approximately 40.0-40.5 billion yuan for 2025, representing a year-on-year decline of 9%-10%, with a net profit attributable to shareholders of about 1.4-2.0 billion yuan, down 66%-76% [1][2]. Financial Performance - In the second half of 2025, the company expects to achieve revenue of 20.1-20.6 billion yuan, a year-on-year decline of 0-3%, and an adjusted net profit of approximately 1.88-2.28 billion yuan, with a change of -7% to +13% [2][3]. - The operating cash flow for the second half of 2025 is projected to grow by 36%-53%, reaching approximately 4.8-5.4 billion yuan [2][3]. - The company anticipates a net cash flow from operating activities of about 9.4-10.0 billion yuan for 2025, reflecting a year-on-year increase of 33%-41% [1][2]. Business Strategy and Market Position - The company is focusing on deepening discipline construction and introducing AI to enhance operations, which is expected to improve revenue and patient visits in the second half of 2025 [2][3]. - The company plans to expand its overseas tumor diagnosis and treatment services, starting in 2025, primarily from its hospital in Chongqing, with potential growth into other hospitals [1][3]. - The company operates 16 hospitals and has ongoing projects that are expected to contribute to future growth, including the opening of new facilities [5]. Industry Trends - The impact of DRGs (Diagnosis-Related Groups) payment reform on average hospitalization costs is expected to diminish, allowing for a potential recovery in overall revenue growth in 2026 [3][4]. - The aging population in China is driving a continuous increase in demand for tumor diagnosis and treatment, positioning the company favorably as a leading comprehensive cancer hospital group [4]. Shareholder Confidence - The company's founder and associated parties have consistently increased their holdings, demonstrating confidence in the company's long-term development [5]. - The company has initiated a share repurchase plan, further indicating its commitment to shareholder returns and long-term growth [5]. Profit Forecast - The company has adjusted its profit forecasts for 2025-2027, expecting revenues of 40.02 billion yuan, 44.59 billion yuan, and 50.19 billion yuan, with respective year-on-year growth rates of -10.00%, 11.44%, and 12.55% [5].

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in Hai Ji Ya Medical (06078.HK) by 434,400 shares on February 5, with a total net increase of 582,800 shares over the last five trading days [1] - Over the past 20 trading days, there have been 13 days of net reductions in holdings by southbound funds, totaling a decrease of 4.3066 million shares [1] - As of now, southbound funds hold 202 million shares of Hai Ji Ya Medical, representing 32.71% of the company's total issued ordinary shares [1] Group 2 - Hai Ji Ya Medical Holdings Limited primarily provides medical services through two business segments, focusing on comprehensive cancer diagnosis and treatment services [1] - The hospital business segment offers multidisciplinary medical services centered around oncology, including radiotherapy, chemotherapy, surgery, and targeted therapies, covering all stages of cancer diagnosis, treatment, and rehabilitation [1] - The other business segment mainly engages in various other operations, with the company primarily operating in the domestic market [1]

海吉亚医疗(06078)发布公告，该公司于2026年2月4日斥资577.69万港元回购43.86万股股份，每股回购 价格为12.96-13.35港元。 ...

智通财经APP讯，海吉亚医疗(06078)发布公告，该公司于2026年2月4日斥资577.69万港元回购43.86万股 股份，每股回购价格为12.96-13.35港元。 ...

格隆汇2月4日丨海吉亚医疗(06078.HK)公告，2月4日耗资577.7万港元回购43.9万股，每股回购价12.96- 13.35港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2026年2月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 海吉亞醫療控股有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註 ...

虽然海吉亚医疗发出盈警，但相信业绩下滑已基本触底。当中，下半年营收同比料跌2%至约20亿元人 民币，而非国际财务报告准则经调整净利润恢复3%正增长，显示盈利韧性正在提升;经调整净利润趋稳 是营运执行力提升的积极讯号。 里昂发布研报称，展望2026年，海吉亚医疗(06078)关键增长动力包括扩张非国家医保目录收入、提升 现有医院利用率，以及降低负债率以推动经营杠杆来重建利润率。该行维持海吉亚医疗的"跑赢大市"评 级，但将目标价由17港元下调至15.9港元。 ...

虽然海吉亚医疗发出盈警，但相信业绩下滑已基本触底。当中，下半年营收同比料跌2%至约20亿元人 民币，而非国际财务报告准则经调整净利润恢复3%正增长，显示盈利韧性正在提升; 经调整净利润趋稳 是营运执行力提升的积极讯号。 智通财经APP获悉，里昂发布研报称，展望2026年，海吉亚医疗(06078)关键增长动力包括扩张非国家医 保目录收入、提升现有医院利用率，以及降低负债率以推动经营杠杆来重建利润率。该行维持海吉亚医 疗的"跑赢大市"评级，但将目标价由17港元下调至15.9港元。 ...